Predictive Value of Cardiac Troponin T in Pediatric Patients at Risk for Myocardial Injury

Steven E Lipshultz; Nader Rifai; Stephen E Sallan; Stuart R Lipsitz; Virginia Dalton; David B Sacks; Michael E Ottlinger

doi:10.1161/01.CIR.96.8.2641

Journal article

Predictive Value of Cardiac Troponin T in Pediatric Patients at Risk for Myocardial Injury

Steven E Lipshultz, Nader Rifai, Stephen E Sallan, Stuart R Lipsitz, Virginia Dalton, David B Sacks and Michael E Ottlinger

Circulation (New York, N.Y.), Vol.96(8), pp.2641-2648

1997-10-21

DOI: https://doi.org/10.1161/01.CIR.96.8.2641

PMID: 9355905

Metrics

31 Record Views

292 Times Cited - Web of Science

InCites Highlights

These are selected metrics from InCites Benchmarking & Analytics tool, related to this output

Collaboration types: Domestic collaboration
Citation topics: 1 Clinical & Life Sciences; 1.219 Cancer Drugs; 1.219.1342 Cardiotoxicity
Web Of Science research areas: Cardiac & Cardiovascular Systems; Peripheral Vascular Disease
ESI research areas: Clinical Medicine

UN Sustainable Development Goals (SDGs)

This output has contributed to the advancement of the following goals:

Source: InCites

Details

Title: Predictive Value of Cardiac Troponin T in Pediatric Patients at Risk for Myocardial Injury
Creators: Steven E Lipshultz - From the Department of Cardiology (S.E.L.), Department of Laboratory Medicine (N.R.), and Division of Hematology-Oncology (S.E.S.), Children’s Hospital, Boston, Mass; the Division of Biostatistics (S.R.L.), and Department of Pediatric Oncology (S.E.S., V.D.), Dana Farber Cancer Institute, Boston; the Department of Pathology (D.B.S.), Brigham and Woman’s Hospital, Boston, Mass; the Department of Biostatistics (S.R.L.), Harvard School of Public Health, Boston, Mass; the Department of Pediatrics (S.E.L
Nader Rifai - From the Department of Cardiology (S.E.L.), Department of Laboratory Medicine (N.R.), and Division of Hematology-Oncology (S.E.S.), Children’s Hospital, Boston, Mass; the Division of Biostatistics (S.R.L.), and Department of Pediatric Oncology (S.E.S., V.D.), Dana Farber Cancer Institute, Boston; the Department of Pathology (D.B.S.), Brigham and Woman’s Hospital, Boston, Mass; the Department of Biostatistics (S.R.L.), Harvard School of Public Health, Boston, Mass; the Department of Pediatrics (S.E.L
Stephen E Sallan - From the Department of Cardiology (S.E.L.), Department of Laboratory Medicine (N.R.), and Division of Hematology-Oncology (S.E.S.), Children’s Hospital, Boston, Mass; the Division of Biostatistics (S.R.L.), and Department of Pediatric Oncology (S.E.S., V.D.), Dana Farber Cancer Institute, Boston; the Department of Pathology (D.B.S.), Brigham and Woman’s Hospital, Boston, Mass; the Department of Biostatistics (S.R.L.), Harvard School of Public Health, Boston, Mass; the Department of Pediatrics (S.E.L
Stuart R Lipsitz - From the Department of Cardiology (S.E.L.), Department of Laboratory Medicine (N.R.), and Division of Hematology-Oncology (S.E.S.), Children’s Hospital, Boston, Mass; the Division of Biostatistics (S.R.L.), and Department of Pediatric Oncology (S.E.S., V.D.), Dana Farber Cancer Institute, Boston; the Department of Pathology (D.B.S.), Brigham and Woman’s Hospital, Boston, Mass; the Department of Biostatistics (S.R.L.), Harvard School of Public Health, Boston, Mass; the Department of Pediatrics (S.E.L
Virginia Dalton - From the Department of Cardiology (S.E.L.), Department of Laboratory Medicine (N.R.), and Division of Hematology-Oncology (S.E.S.), Children’s Hospital, Boston, Mass; the Division of Biostatistics (S.R.L.), and Department of Pediatric Oncology (S.E.S., V.D.), Dana Farber Cancer Institute, Boston; the Department of Pathology (D.B.S.), Brigham and Woman’s Hospital, Boston, Mass; the Department of Biostatistics (S.R.L.), Harvard School of Public Health, Boston, Mass; the Department of Pediatrics (S.E.L
David B Sacks - From the Department of Cardiology (S.E.L.), Department of Laboratory Medicine (N.R.), and Division of Hematology-Oncology (S.E.S.), Children’s Hospital, Boston, Mass; the Division of Biostatistics (S.R.L.), and Department of Pediatric Oncology (S.E.S., V.D.), Dana Farber Cancer Institute, Boston; the Department of Pathology (D.B.S.), Brigham and Woman’s Hospital, Boston, Mass; the Department of Biostatistics (S.R.L.), Harvard School of Public Health, Boston, Mass; the Department of Pediatrics (S.E.L
Michael E Ottlinger - From the Department of Cardiology (S.E.L.), Department of Laboratory Medicine (N.R.), and Division of Hematology-Oncology (S.E.S.), Children’s Hospital, Boston, Mass; the Division of Biostatistics (S.R.L.), and Department of Pediatric Oncology (S.E.S., V.D.), Dana Farber Cancer Institute, Boston; the Department of Pathology (D.B.S.), Brigham and Woman’s Hospital, Boston, Mass; the Department of Biostatistics (S.R.L.), Harvard School of Public Health, Boston, Mass; the Department of Pediatrics (S.E.L
Publication Details: Circulation (New York, N.Y.), Vol.96(8), pp.2641-2648
Academic Unit: UMMG Department of Pediatrics
Language: English
Resource Type: Journal article
PMID: 9355905
Record Identifier: 991031577379202976